Vimarsana
Biggest News Aggregation in the World

Biomarker Analyses News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biomarker Analyses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biomarker Analyses Today - Breaking & Trending Today

Withings Unveils Mini At-Home Urine Analysis Platform for Clinical Trials & RPM - Vimarsana News

Withings Unveils Mini At-Home Urine Analysis Platform for Clinical Trials & RPM

Withings unveiled, U-Scan, a miniaturized pebble-shaped urine analysis reader that sits within the toilet bowl to monitor vitals from home.

Withings Announces U-Scan - The World's First Hands-free Connected Home Urine Lab - Vimarsana News

Withings Announces U-Scan - The World's First Hands-free Connected Home Urine Lab

/PRNewswire/ -- Following four years of development, Withings, global leader in connected health is proud to announce U-Scan, a breakthrough in-home biomarker...

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022 - Vimarsana News

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

Junshi Biosciences Highlights Pipeline Advances in - Vimarsana News

Junshi Biosciences Highlights Pipeline Advances in

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors ...

Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022 - Vimarsana News

Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

--Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors --Toripalimab continues to demonstrate synergy as the